Biotech IPOs lead US markets in 2026, outpacing AI listings as healthcare innovation takes center stage over artificial intelligence.
Scribe Therapeutics, with Eli Lilly’s backing, files for a $107.2 million IPO, highlighting gene-editing sector momentum and potential biotech IPO revival.
Apnimed, backed by Japanese drugmaker Shionogi, files IPO to raise capital for Phase 3 trial of oral sleep apnea therapy, targeting a…
AstraZeneca stock drops following unexpected failure of a heart disease drug trial.
Amgen’s Tavneos faces EU withdrawal after regulators question clinical data integrity, threatening a growth driver and pressuring AMGN shares.
Biotech Kardigan gained nearly 2% in its stock market debut after completing a $400 million initial public offering that priced at the…
Kardigan's upsized $400 million IPO for heart disease therapies highlights growing investor confidence in biotech innovation and sets a favorable precedent for…
Prime Radiant backs Cellares with $50M as the biotech firm gears up for a 2027 IPO, underscoring investor appetite for pre-public opportunities…
Heart health biotech Kardigan files for a $373.3 million U.S. IPO, signaling growing investor interest in cardiovascular therapies and testing the IPO…
Parabilis stock skyrocketed 67% after the drugmaker completed a $745 million IPO and private placement, marking one of the largest biotech IPOs…
Parabilis completes $745 million US IPO, indicating robust biotech investor appetite and potential gains for biotech ETFs.
The Netherlands expands foreign investment screening to AI and biotech, signaling heightened regulatory scrutiny that could derail foreign acquisitions of Dutch tech…